Directive 2004/27 - Amendment of Directive 2001/83/EC on the EC code relating to medicinal products for human use - Main contents
Please note
This page contains a limited version of this dossier in the EU Monitor.
Contents
official title
Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human useLegal instrument | Directive |
---|---|
Number legal act | Directive 2004/27 |
Original proposal | COM(2001)404 ![]() |
CELEX number i | 32004L0027 |
Document | 31-03-2004 |
---|---|
Publication in Official Journal | 30-04-2004; Special edition in Maltese: Chapter 13 Volume 034,Special edition in Romanian: Chapter 13 Volume 044,Special edition in Polish: Chapter 13 Volume 034,Special edition in Croatian: Chapter 13 Volume 061,Special edition in Lithuanian: Chapter 13 Volume 034,Special edition in Slovenian: Chapter 13 Volume 034,Special edition in Bulgarian: Chapter 13 Volume 044,Special edition in Slovak: Chapter 13 Volume 034,Special edition in Estonian: Chapter 13 Volume 034,OJ L 136, 30.4.2004,Special edition in Czech: Chapter 13 Volume 034,Special edition in Latvian: Chapter 13 Volume 034,Special edition in Hungarian: Chapter 13 Volume 034 |
Effect | 30-04-2004; Entry into force Date pub. See Art 4 |
End of validity | 31-12-9999 |
Transposition | 30-10-2005; At the latest See Art 3 |
|
Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use (Text with EEA relevance)
Official Journal L 136 , 30/04/2004 P. 0034 - 0057
Directive 2004/27/EC of the European Parliament and of the Council
of 31 March 2004
amending Directive 2001/83/EC on the Community code relating to medicinal products for human use
THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION,
Having regard to the Treaty establishing the European Community, and in particular Article 95 thereof,
Having regard to the proposal by the Commission(1),
Having regard to the Opinion of the European Economic and Social Committee(2),
After consulting the Committee of the Regions,
Acting in accordance with the procedure laid down in Article 251 of the Treaty(3),
Whereas:
-
(1)Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use(4), codified and consolidated in a single text the texts of Community legislation on medicinal products for human use, in the interests of clarity and rationalisation.
-
(2)The Community legislation so far adopted has made a major contribution to the achievement of the objective of the free and safe movement of medicinal products for human use and the elimination of obstacles to trade in such products. However, in the light of the experience acquired, it has become clear that new measures are necessary to eliminate the remaining obstacles to free movement.
-
(3)It is therefore necessary to align the national laws, regulations and administrative provisions which contain differences with regard to the basic principles in order to promote the operation of the internal market while realising a high level of human health protection.
-
(4)The main purpose of any regulation on the manufacture and distribution of medicinal products for human use should be to safeguard public health. However, this objective should be achieved by means which do not hinder the development of the pharmaceutical industry or trade in medicinal products in the Community.
-
(5)Article 71 of Council Regulation (EEC) No 2309/93 of 22 July 1993 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Agency for the Evaluation of Medicinal Products(5) provided that, within six years of its entry into force, the Commission was required to publish a general report on the experience acquired as a result of the operation of the marketing authorisation procedures laid down in that Regulation and in other Community legal provisions.
-
(6)In the light of the Commission's report on the experience acquired, it has proved necessary to improve the operation of the marketing authorisation procedures for medicinal products in the Community.
-
(7)Particularly as a result of scientific and technical progress, the definitions and scope of Directive 2001/83/EC should be clarified in order to achieve high standards for the quality, safety and efficacy of medicinal products for human use. In order to take account both of the emergence of new therapies and of the growing number of so-called "borderline" products between the medicinal product sector and other sectors, the definition of "medicinal product" should be modified so as to avoid any doubt as to the applicable legislation when a product, whilst fully falling within the definition of a medicinal product, may also fall within the definition of other regulated products. This definition should specify the type of action that the medicinal product may exert on physiological functions. This enumeration of actions will also make it possible to cover medicinal products...
More
This text has been adopted from EUR-Lex.
This dossier is compiled each night drawing from aforementioned sources through automated processes. We have invested a great deal in optimising the programming underlying these processes. However, we cannot guarantee the sources we draw our information from nor the resulting dossier are without fault.
This page is also available in a full version containing the legal context, de Europese rechtsgrond, other dossiers related to the dossier at hand and the related cases of the European Court of Justice.
The full version is available for registered users of the EU Monitor by ANP and PDC Informatie Architectuur.
The EU Monitor enables its users to keep track of the European process of lawmaking, focusing on the relevant dossiers. It automatically signals developments in your chosen topics of interest. Apologies to unregistered users, we can no longer add new users.This service will discontinue in the near future.